
pmid: 10100083
handle: 11588/435996 , 11368/2296662 , 11388/56947 , 11577/135265 , 2318/34389
The aim of this study was to evaluate the effect of trandolapril, an angiotensin converting enzyme inhibitor, on blood pressure, forearm blood flow and insulin sensitivity in comparison with nifedipine gastrointestinal therapeutic system.This is a multicentre, two-way parallel-group, open-label comparative study in 90 overweight hypertensive patients, who were randomly assigned to treatment for 8 weeks with either trandolapril or nifedipine. At baseline and after treatment, all patients underwent an oral glucose tolerance test, an evaluation of their metabolic profiles and a euglycaemic hyperinsulinaemic clamp test. In a subgroup of 18 patients, a forearm study was carried out.Blood pressure fell by the second week of treatment and remained significantly reduced compared with baseline in both treatment groups. Plasma triglyceride levels were also significantly reduced after trandolapril therapy, but no significant changes occurred in the other metabolic parameters during treatment with either drug. During the euglycaemic hyperinsulinaemic clamp, whole-body glucose use was similar in the two treatment groups at baseline, and a moderate but statistically significant increase in insulin sensitivity was observed after trandolapril treatment (trandolapril: 5.0 +/- 0.2 versus 4.5 +/- 0.2 mg/kg per min; nifedipine: 4.1 +/- 0.3 versus 4.2 +/- 0.3 mg/kg per min; P < 0.05, versus baseline and trandolapril versus nifedipine treatment). Skeletal muscle glucose uptake was significantly higher after trandolapril than after nifedipine therapy (5.0 +/- 0.7 and 3.0 +/- 0.4 mg/min, respectively; P < 0.01). As forearm blood flow was similar in the two treatment groups at baseline and was unchanged after 8 weeks of therapy, skeletal muscle glucose extraction was significantly greater in the ACE inhibitor treated-group than in the nifedipine comparative group (trandolapril: baseline 21 +/- 2, treatment 24 +/- 3 mg/dl; nifedipine: baseline 18 +/- 3, treatment 16 +/- 2 mg/dl; P < 0.05, trandolapril versus nifedipine treatment).During short-term treatment, ACE inhibition with trandolapril was able to moderately improve insulin sensitivity, in comparison with calcium blockade, and this effect appeared to be independent of the haemodynamic action of the drug.
Adult, Male, hypertension, Indoles, Nifedipine, Angiotensin-Converting Enzyme Inhibitors, Blood Pressure, Peptidyl-Dipeptidase A, ACE inhibition; insulin sensitivity; human; hypertension; blood flow, ace inhibitors; antihypertensive treatment; clinical trial, blood, insulin sensitivity, blood flow, Humans, blood supply/metabolism, human, Obesity, complications/metabolism, Muscle, Skeletal, Aged, complications/drug therapy/metabolism, Adult, Aged, Angiotensin-Converting Enzyme Inhibitors; therapeutic use, Blood Flow Velocity, Blood Pressure; drug effects, Calcium Channel Blockers; therapeutic use, Calcium; blood, Female, Follow-Up Studies, Forearm; blood supply, Glucose Tolerance Test, Glucose; metabolism, Humans, Hypertension; complications/drug therapy/metabolism, Indoles; therapeutic use, Insulin Resistance; physiology, Italy, Male, Middle Aged, Muscle; Skeletal; blood supply/metabolism, Nifedipine; therapeutic use, Obesity; complications/metabolism, Peptidyl-Dipeptidase A; blood/drug effects, Treatment Outcome, ACE inhibition, Skeletal, Glucose Tolerance Test, Middle Aged, Calcium Channel Blockers, blood supply, Forearm, Treatment Outcome, Glucose, Italy, therapeutic use, drug effects, physiology, Hypertension, Muscle, Calcium, Female, blood/drug effects, Insulin Resistance, metabolism, Blood Flow Velocity, Follow-Up Studies
Adult, Male, hypertension, Indoles, Nifedipine, Angiotensin-Converting Enzyme Inhibitors, Blood Pressure, Peptidyl-Dipeptidase A, ACE inhibition; insulin sensitivity; human; hypertension; blood flow, ace inhibitors; antihypertensive treatment; clinical trial, blood, insulin sensitivity, blood flow, Humans, blood supply/metabolism, human, Obesity, complications/metabolism, Muscle, Skeletal, Aged, complications/drug therapy/metabolism, Adult, Aged, Angiotensin-Converting Enzyme Inhibitors; therapeutic use, Blood Flow Velocity, Blood Pressure; drug effects, Calcium Channel Blockers; therapeutic use, Calcium; blood, Female, Follow-Up Studies, Forearm; blood supply, Glucose Tolerance Test, Glucose; metabolism, Humans, Hypertension; complications/drug therapy/metabolism, Indoles; therapeutic use, Insulin Resistance; physiology, Italy, Male, Middle Aged, Muscle; Skeletal; blood supply/metabolism, Nifedipine; therapeutic use, Obesity; complications/metabolism, Peptidyl-Dipeptidase A; blood/drug effects, Treatment Outcome, ACE inhibition, Skeletal, Glucose Tolerance Test, Middle Aged, Calcium Channel Blockers, blood supply, Forearm, Treatment Outcome, Glucose, Italy, therapeutic use, drug effects, physiology, Hypertension, Muscle, Calcium, Female, blood/drug effects, Insulin Resistance, metabolism, Blood Flow Velocity, Follow-Up Studies
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 40 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
